SecBot SecBot
8-K ·Filed Apr 7, 2026

STOK

Stoke Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001193125-26-145524
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

The appointment signals a focus on regulatory preparedness for zorevunersen. Traders should monitor for upcoming Phase 3 data readouts and potential regulatory milestones, which this addition to the board may help facilitate.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$34.87
T+0 close · Apr 7, 2026 · via day close
Latest settled
−6.22%
T+60 · $32.70
Vs SPY
−16.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $34.87entry
  2. T+1 · 7mo ago +0.80%α +0.23% · $35.15
  3. T+5 · 7mo ago +1.92%α −1.60% · $35.54
  4. T+20 · 7mo ago −5.48%α −14.02% · $32.96
  5. T+60 · 4mo ago −6.22%α −16.68% · $32.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expertise, to its board of directors. The move strengthens governance ahead of key Phase 3 data readouts for its lead candidate, zorevunersen, in Dravet syndrome.

Key Facts

  • Dr. G. Clare Kahn, Ph.D., was appointed to Stoke's Board of Directors effective April 3, 2026.
  • Dr. Kahn brings over three decades of industry experience, including senior roles at Pfizer, GSK, and X-VAX Technology Inc., with expertise in rare disease drug development and regulatory strategy.
  • She was also appointed chairperson of the Research and Development Committee and to the Nominating and Corporate Governance Committee.
  • The board size was increased to ten directors to accommodate the appointment.
  • Dr. Kahn received an initial stock option grant valued at approximately $724,000 and will receive an annual cash retainer of $45,000.

Financial Impact

Approximately $724,000 in initial stock option grant value and $45,000 annual cash retainer for Dr. Kahn's board service.

equity compensationoperating expenses

Risk Factors

  • Biotech clinical-stage risk: The company's value is highly dependent on the success of zorevunersen, which is still in development.
  • Dilution risk: The stock option grant, while standard for board appointments, represents a small degree of shareholder dilution.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-145524
Document: d63742dex991.htm0001193125-26-145524
Document: 0001193125-26-145524-index-headers.html0001193125-26-145524
Document: 0001193125-26-145524-index.html0001193125-26-145524
Document: 0001193125-26-145524.txt0001193125-26-145524

US Market Status

Market Closed · Opens in 8h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026